December 3, 2021 10:55 AM EST

Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint

Josh Sullivan

Paul Schloesser

Associate Editor

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint

Josh Sullivan

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Associate Editor

Sign up to read this article for free.

more like this

Biospecimen M&A: Discovery acquires Albert Li's hepatocyte project; PhIII trial on Bayer's Nubeqa reached primary endpoint